Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550104 | 1.00 | SIGMAR1 (0.59) | SIGMAR1BCHETACR1TSHRALDH1A1 | |
| SCHEMBL2715155 | 0.89 | BCHE (0.56) | SIGMAR1BCHEALDH1A1CA1CA2 | |
| SCHEMBL9625673 | 0.86 | SIGMAR1 (0.59) | SIGMAR1BCHETACR1TSHRCA1 | |
| SCHEMBL21444695 | 0.81 | TAAR1 (0.57) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL25666197 | 0.81 | TAAR1 (0.57) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL28751212 | 0.81 | CTSS (0.47) | SIGMAR1TACR1TSHRCYP2D6CA1 | |
| SCHEMBL13995917 | 0.80 | TACR1 (0.46) | SIGMAR1BCHETACR1TSHRCA1 | |
| SCHEMBL3559030 | 0.80 | TSHR (0.50) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL27526858 | 0.80 | MAOA (0.58) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL1006250 | 0.79 | SIGMAR1 (0.51) | SIGMAR1BCHEALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-25 | — | — | US | disclosed |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-04-14 | — | — | US | disclosed |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-08-15 | — | — | US | disclosed |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The USA, as represented by the Secretary, Departme nt of Health and Human Services (US) | 2019-01-10 | — | — | US | disclosed |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-20 | — | — | US | disclosed |
| EP-2544676-B1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | US HEALTH (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2018-05-24 | — | — | US | disclosed |
| US-8703826-B2 | Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101528666-B | Preparation of (R, R) -fenoterol and (R, R) -or (R, S) -fenoterol analogues and their use in the treatment of congestive heart failure | US GOV HEALTH & HUMAN SERV (US) | 2014-01-29 | — | — | CN | disclosed |
| EP-2544676-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | SRI INTERNATIONAL | 2013-01-03 | — | — | US | disclosed |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | Services, National Institutes of Health | 2012-06-21 | — | — | US | disclosed |
| WO-2011112867-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-07-01 | — | — | US | disclosed |
| CN-101528666-A | Preparation of (R, R) -fenoterol and (R, R) -or (R, S) -fenoterol analogues and their use in the treatment of congestive heart failure | US GOVERNMENT (US) | 2009-09-09 | — | — | CN | disclosed |
| EP-2064174-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008022038-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141894-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TACR1 51/4885 |
| US-10617654-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TACR1 83/4885 |
| US-10562843-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TACR1 51/4885 |
| US-20130005799-A1 | THE USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 458/4885BCHE 3789/4885TACR1 80/4885 |
| US-20120157543-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TACR1 51/4885 |
| US-10308591-B2 | Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure | ADRB2, ADRB1, ADRB3 | SIGMAR1 332/4885BCHE 3059/4885TACR1 57/4885 |
| US-20100168245-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TACR1 51/4885 |
| US-20200197332-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TACR1 83/4885 |
| US-20190248732-A1 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)- OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE | ADRB2, ADRB1, ADRB3 | SIGMAR1 341/4885BCHE 2926/4885TACR1 51/4885 |
| US-10925840-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TACR1 83/4885 |
| US-20190008802-A1 | USE OF FENOTEROL AND FENOTEROL ANALOGUES IN THE TREATMENT OF GLIOBLASTOMAS AND ASTROCYTOMAS | ADRB2, ADRB1, ADRA2A | SIGMAR1 363/4885BCHE 4100/4885TACR1 83/4885 |
| US-10130594-B2 | Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | ADRB2, ADRB1, ADRA2A | SIGMAR1 364/4885BCHE 4133/4885TACR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.